CervoMed Inc.·Healthcare

Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible

Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design

CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ: ILMN) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 299,361 shares of the life sciences company's stock after selling 12,818 shares during the period. CIBC

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial

Illumina (NASDAQ: ILMN - Get Free Report) and CervoMed (NASDAQ: CRVO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Analyst Ratings This is a summary of current recommendations and
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.